Patent · US Active

Anti-CTLA4 antibodies and methods of making and using the same

US11359016B2 · kind B2 · utility

4Cited by

22References

40Claims

0Family size

Assignee

Adagene Inc. · KY

Inventors

Peter Peizhi Luo · San Mateo, US
Fangyong Du · 安丰镇, CN
Zhongzong PAN · Suzhou, CN
Guizhong LIU · Suzhou, CN

Key dates

Filing date	Feb 1, 2019
Grant date	Jun 14, 2022
Priority date	—
Expiry date	Dec 23, 2039

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC07K2319/70
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

Provided herein are cross-reactive antibodies (or antigen binding fragments thereof) that bind to human CTLA4, activatable antibodies that bind to human CTLA4, nucleic acid molecules encoding the same, pharmaceutical compositions thereof, and methods of their therapeutic use (e.g., for treatment of cancer).

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.